Compare NBTX & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | ADMA |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2018 | 2012 |
| Metric | NBTX | ADMA |
|---|---|---|
| Price | $39.70 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $36.00 | $25.67 |
| AVG Volume (30 Days) | 103.7K | ★ 3.0M |
| Earning Date | 03-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $58.17 | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | ★ N/A | $44.05 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $6.09 | $7.21 |
| 52 Week High | $57.14 | $20.46 |
| Indicator | NBTX | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 38.31 |
| Support Level | $38.89 | $8.23 |
| Resistance Level | $42.40 | $8.97 |
| Average True Range (ATR) | 2.49 | 0.26 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 64.01 | 8.58 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.